查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703366

轉化再生醫學市場－全球產業規模、佔有率、趨勢、機會和預測（按產品類型、應用、地區和競爭細分，2020-2030 年）

Translational Regenerative Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球轉化再生醫學市場價值為 34.2 億美元，預計到 2030 年將達到 62.8 億美元，預測期內的年複合成長率(CAGR) 為 10.64%。轉化再生醫學是連結基礎科學研究和臨床應用的多學科領域，重點是透過再生療法恢復或增強受損或患病組織和器官的結構和功能。

市場概覽
預測期 2026-2030
2024年市場規模 34.2億美元
2030年市場規模 62.8億美元
2025-2030 年複合年成長率 10.64%
成長最快的領域 腫瘤學
最大的市場 北美洲

這個不斷發展的領域涵蓋了整個醫療創新管道——從基礎研究和臨床前研究到臨床試驗，並最終融入醫療實踐。它本質上是迭代的，臨床見解反饋到研究中，以不斷改進和擴展治療選擇。心血管疾病、糖尿病、神經退化性疾病和肌肉骨骼疾病等慢性疾病的盛行率不斷上升，加上全球人口老化，加劇了對先進的再生治療替代方案的需求，從而推動了市場成長。

關鍵市場促進因素

再生醫學的技術進步

主要市場挑戰

患者就診受限和報銷障礙

基於地理位置、社會經濟地位和保險可用性的醫療服務差異進一步加劇了這些挑戰，引發了人們對公平醫療服務的擔憂。

主要市場趨勢

再生療法中的個人化醫療

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球轉化再生醫學市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品類型（細胞產品、基因治療產品、組織工程產品）
    • 依應用（心血管、皮膚科、糖尿病、神經學、腫瘤學、骨科）
    • 按公司分類（2024）
  • 市場地圖

第6章：亞太地區轉化再生醫學市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第7章：歐洲轉化再生醫學市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第8章：北美轉化再生醫學市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第9章：南美洲轉化再生醫學市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲轉化再生醫學市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球轉化再生醫學市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

  • Astellas Pharma Inc.
  • Athersys, Inc.
  • AVITA Medical
  • Axogen Corporation
  • Gamida Cell Ltd.
  • Integra LifeSciences Corporation
  • Medtronic PLC
  • Mesoblast Ltd.
  • Novartis AG
  • Spark Therapeutics, Inc.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 16880

Global Translational Regenerative Medicine Market was valued at USD 3.42 billion in 2024 and is projected to reach USD 6.28 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.64% over the forecast period. Translational regenerative medicine represents a multidisciplinary domain bridging fundamental scientific research and clinical application, with a focus on restoring or enhancing the structure and function of damaged or diseased tissues and organs through regenerative therapies.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.42 Billion
Market Size 2030USD 6.28 Billion
CAGR 2025-203010.64%
Fastest Growing SegmentOncology
Largest MarketNorth America

This evolving field encompasses the entire medical innovation pipeline-from basic research and preclinical studies to clinical trials and eventual integration into healthcare practice. It is inherently iterative, with clinical insights feeding back into research to continually improve and expand therapeutic options. The rising prevalence of chronic conditions such as cardiovascular diseases, diabetes, neurodegenerative disorders, and musculoskeletal ailments, along with an aging global population, is intensifying the demand for advanced, regenerative treatment alternatives-thereby driving market growth.

Key Market Drivers

Technological Advancements in Regenerative Medicine

Breakthrough technologies are reshaping regenerative medicine, unlocking transformative opportunities for treatment development across a spectrum of medical conditions. One notable advancement is 3D bioprinting, which enables the precise layer-by-layer construction of tissues and organs using biomaterials, living cells, and growth factors. This innovation supports the creation of tailor-made tissues and holds promise for organ transplantation and tissue regeneration.

Gene-editing technologies, particularly CRISPR-Cas9, have revolutionized the ability to modify genetic material with high precision. These tools facilitate the correction of genetic mutations, the engineering of therapeutic cells, and the development of targeted gene therapies.

Another key development is induced pluripotent stem cell (iPSC) technology, which allows adult cells to be reprogrammed into a pluripotent state. iPSCs can be differentiated into any cell type and used to create personalized cell lines for disease modeling, drug testing, and patient-specific treatments-minimizing immune rejection and enhancing clinical efficacy.

Key Market Challenges

Limited Patient Access and Reimbursement Hurdles

Access to regenerative therapies remains a significant challenge due to the high costs associated with research, development, and administration. Many treatments-such as stem cell and gene therapies-are expensive and may not be fully covered by insurance providers, who often classify these therapies as experimental or investigational. As a result, patients may face substantial out-of-pocket expenses.

The reimbursement framework for regenerative medicine is still in a developmental phase, with considerable variation across regions and healthcare systems. This inconsistency creates uncertainty for providers and patients alike. Furthermore, the regulatory approval process for regenerative therapies is often lengthy and complex, delaying patient access, particularly in urgent medical cases.

In many instances, regenerative therapies lack extensive long-term data on safety and efficacy, which can influence payer confidence and slow reimbursement decisions. Administrative requirements such as prior authorizations can also introduce delays, while healthcare providers may face operational challenges due to insufficient infrastructure or experience in managing reimbursement for advanced therapies.

Disparities in access based on geographic location, socioeconomic status, and insurance availability further compound these challenges, raising concerns about equitable healthcare delivery.

Key Market Trends

Personalized Medicine in Regenerative Therapies

Personalized medicine is emerging as a transformative trend within regenerative medicine, enabling the development of highly tailored treatments based on an individual's genetic and cellular profile. Technologies such as iPSCs derived from a patient's own cells are being used to generate specific cell types for targeted therapy. This approach reduces the risk of immune rejection and enhances therapeutic effectiveness.

Genomic data is increasingly used to guide treatment selection. Genetic testing can identify mutations or polymorphisms that impact a patient's response to certain therapies, allowing clinicians to choose the most appropriate regenerative treatment strategies.

Moreover, patient-specific disease models, developed using iPSCs, provide valuable insights into disease mechanisms, supporting the development of personalized drug regimens and regenerative protocols. Customized dosage, treatment timing, and delivery methods are optimized based on individual health profiles, which can improve therapeutic outcomes and minimize adverse effects.

In oncology, personalized regenerative approaches are driving innovation in cancer immunotherapy. Autologous therapies such as CAR-T cell therapy involve modifying a patient's own immune cells to recognize and combat cancer. These treatments are customized according to the patient's cancer subtype and genetic makeup.

Personalized medicine also emphasizes ongoing monitoring, utilizing biomarkers and genomic data to assess therapeutic response in real-time, enabling dynamic adjustments to treatment plans and ensuring optimal patient outcomes.

Key Market Players

  • Astellas Pharma Inc.
  • Athersys, Inc.
  • AVITA Medical
  • Axogen Corporation
  • Gamida Cell Ltd.
  • Integra LifeSciences Corporation
  • Medtronic PLC
  • Mesoblast Ltd.
  • Novartis AG
  • Spark Therapeutics Inc.

Report Scope:

In this report, the Global Translational Regenerative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Translational Regenerative Medicine Market, By Product Type:

  • Cell Based Product
  • Gene Therapy Product
  • Tissue Engineered Product

Translational Regenerative Medicine Market, By Application:

  • Cardiovascular
  • Dermatology
  • Diabetes
  • Neurology
  • Oncology
  • Orthopedic

Translational Regenerative Medicine Market, By region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Translational Regenerative Medicine Market.

Available Customizations:

Global Translational Regenerative Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Translational Regenerative Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Cell Based Product, Gene Therapy Product, Tissue Engineered Product)
    • 5.2.2. By Application (Cardiovascular, Dermatology, Diabetes, Neurology, Oncology, Orthopedic)
    • 5.2.3. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Translational Regenerative Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Translational Regenerative Medicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
    • 6.3.2. India Translational Regenerative Medicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Australia Translational Regenerative Medicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
    • 6.3.4. Japan Translational Regenerative Medicine Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product Type
        • 6.3.4.2.2. By Application
    • 6.3.5. South Korea Translational Regenerative Medicine Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product Type
        • 6.3.5.2.2. By Application

7. Europe Translational Regenerative Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Translational Regenerative Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Translational Regenerative Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Spain Translational Regenerative Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Translational Regenerative Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
    • 7.3.5. United Kingdom Translational Regenerative Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application

8. North America Translational Regenerative Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Translational Regenerative Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Mexico Translational Regenerative Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Canada Translational Regenerative Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application

9. South America Translational Regenerative Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Translational Regenerative Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Translational Regenerative Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Translational Regenerative Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application

10. Middle East and Africa Translational Regenerative Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Translational Regenerative Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Translational Regenerative Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Translational Regenerative Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Translational Regenerative Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Astellas Pharma Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Athersys, Inc.
  • 16.3. AVITA Medical
  • 16.4. Axogen Corporation
  • 16.5. Gamida Cell Ltd.
  • 16.6. Integra LifeSciences Corporation
  • 16.7. Medtronic PLC
  • 16.8. Mesoblast Ltd.
  • 16.9. Novartis AG
  • 16.10. Spark Therapeutics, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer